EDIT
Price
$1.82
Change
+$0.05 (+2.82%)
Updated
Jun 3 closing price
Capitalization
152.36M
56 days until earnings call
ENTA
Price
$7.19
Change
+$0.90 (+14.31%)
Updated
Jun 3 closing price
Capitalization
153.7M
68 days until earnings call
Interact to see
Advertisement

EDIT vs ENTA

Header iconEDIT vs ENTA Comparison
Open Charts EDIT vs ENTABanner chart's image
Editas Medicine
Price$1.82
Change+$0.05 (+2.82%)
Volume$1.66M
Capitalization152.36M
Enanta Pharmaceuticals
Price$7.19
Change+$0.90 (+14.31%)
Volume$345.07K
Capitalization153.7M
EDIT vs ENTA Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. ENTA commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Buy and ENTA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (EDIT: $1.82 vs. ENTA: $7.19)
Brand notoriety: EDIT and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 86% vs. ENTA: 178%
Market capitalization -- EDIT: $152.36M vs. ENTA: $153.7M
EDIT [@Biotechnology] is valued at $152.36M. ENTA’s [@Biotechnology] market capitalization is $153.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileENTA’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • ENTA’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than ENTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 6 TA indicator(s) are bullish while ENTA’s TA Score has 6 bullish TA indicator(s).

  • EDIT’s TA Score: 6 bullish, 4 bearish.
  • ENTA’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а +10.30% price change this week, while ENTA (@Biotechnology) price change was +23.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.74%. For the same industry, the average monthly price growth was +2.75%, and the average quarterly price growth was +0.73%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

ENTA is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+5.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ENTA($154M) and EDIT($152M) have the same market capitalization . EDIT YTD gains are higher at: 43.307 vs. ENTA (25.043). ENTA has higher annual earnings (EBITDA): -94.42M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. ENTA (217M). EDIT has less debt than ENTA: EDIT (35M) vs ENTA (57.5M). ENTA has higher revenues than EDIT: ENTA (66.6M) vs EDIT (32.3M).
EDITENTAEDIT / ENTA
Capitalization152M154M99%
EBITDA-233.11M-94.42M247%
Gain YTD43.30725.043173%
P/E RatioN/AN/A-
Revenue32.3M66.6M48%
Total Cash270M217M124%
Total Debt35M57.5M61%
FUNDAMENTALS RATINGS
EDIT vs ENTA: Fundamental Ratings
EDIT
ENTA
OUTLOOK RATING
1..100
209
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
9550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for ENTA (96). This means that EDIT’s stock grew somewhat faster than ENTA’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ENTA (100). This means that EDIT’s stock grew similarly to ENTA’s over the last 12 months.

EDIT's SMR Rating (95) in the Biotechnology industry is in the same range as ENTA (95). This means that EDIT’s stock grew similarly to ENTA’s over the last 12 months.

EDIT's Price Growth Rating (61) in the Biotechnology industry is in the same range as ENTA (63). This means that EDIT’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that ENTA’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITENTA
RSI
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
68%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
70%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 14 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
INTIX12.78N/A
N/A
Voya International Index Port S
LIDRX9.71N/A
N/A
Lord Abbett International Value R2
AZNIX11.69N/A
N/A
Virtus Income & Growth Inst
GSZPX26.28N/A
N/A
Goldman Sachs Small Cap Gr Insghts P
PISYX11.45N/A
N/A
Victory Pioneer Intrinsic Value Y

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+2.82%
CRSP - EDIT
55%
Loosely correlated
+2.95%
AXON - EDIT
52%
Loosely correlated
+0.07%
PRME - EDIT
50%
Loosely correlated
+11.76%
VCYT - EDIT
49%
Loosely correlated
-0.90%
NTLA - EDIT
48%
Loosely correlated
+7.40%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+14.31%
ALEC - ENTA
42%
Loosely correlated
+7.25%
BEAM - ENTA
38%
Loosely correlated
+4.26%
ERAS - ENTA
37%
Loosely correlated
+1.40%
ADCT - ENTA
37%
Loosely correlated
+2.28%
KRYS - ENTA
37%
Loosely correlated
+4.43%
More